Welcome to our dedicated page for Turn Therapeutics SEC filings (Ticker: TTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Turn Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Turn Therapeutics's regulatory disclosures and financial reporting.
Turn Therapeutics Inc. reported an insider stock purchase by officer Zuraiz Chaudhary. On 12/12/2025, Chaudhary bought 2,500 shares of common stock at $3.5 per share, bringing their directly held beneficial ownership to 12,500 shares.
Chaudhary serves as Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer, and this report covers a single reporting person with direct ownership of the common stock.
Turn Therapeutics Inc. (TTRX) filed a Form 4 reporting a stock purchase by a director. On 11/24/2025, a reporting person serving as a director acquired 9,868 shares of Turn Therapeutics common stock in an open-market transaction coded "P" for purchase.
The weighted average purchase price was $3.44 per share, with individual trades executed between $3.25 and $3.50. Following this transaction, the reporting person beneficially owns 60,602 shares of Turn Therapeutics common stock, which includes restricted stock units granted under the company’s 2025 Omnibus Incentive Plan. Each RSU represents a right to receive one share of common stock, subject to vesting and continued service.
Turn Therapeutics Inc. (TTRX)11/21/2025, the reporting person bought 20,532 shares of common stock in an open-market transaction at a weighted average price of $2.87 per share, with individual trades ranging from $2.66 to $3.25. After this transaction, the director beneficially owns 50,734 shares of common stock.
Certain shares in this total are restricted stock units (RSUs) granted under Turn Therapeutics’ 2025 Omnibus Incentive Plan, each RSU representing a right to receive one common share if vesting conditions and continued service requirements are satisfied.
Turn Therapeutics Inc. (TTRX)11/20/2025, the officer bought 1,450 shares of common stock at $2.61 per share, followed by another purchase of 1,000 shares at $3.29 per share on 11/21/2025. After these transactions, the officer beneficially owned 10,000 shares of Turn Therapeutics common stock, held directly.
FAQ
What is the current stock price of Turn Therapeutics (TTRX)?
What is the market cap of Turn Therapeutics (TTRX)?
